Decision to complete the stock split at a ratio of 1:20

At the annual general meeting of ALK-Abelló (ALKB: DC / OMX: ALK B / AKABY / AKBLF) on March 16, 2022, the general meeting decided to change the denomination of the nominal value of each share from 10 DKK to 0.50 DKK or a multiple thereof. The change in the nominal value of the shares allows the board of directors of ALK-Abelló A/S to carry out a stock split.

On this basis, the Board of Directors has decided to proceed with a share split in a ratio of 1:20 implying that each existing share with a nominal value of DKK 10 will be divided into 20 new shares with a nominal value of DKK 0.50 each. Following the stock split, the company’s share capital of DKK 111,411,960 will be divided into 18,415,200 A shares, 1,841,520 AA shares and 202,567,200 B shares, each with a nominal value of DKK 0.50. Following the stock split, each A share and AA share with a nominal value of DKK 0.50 will have 10 votes and each B share with a nominal value of DKK 0.50 will have one vote.

The expected timetable for the completion of the split of the company’s B shares listed on Nasdaq Copenhagen will be as follows:

  • March 25, 2022: Last day of trading on Nasdaq Copenhagen via existing ISIN code DK0060027142
  • March 28, 2022: First day of trading on Nasdaq Copenhagen via new ISIN code DK0061802139
  • March 29, 2022: The new ISIN code and the face value (nominal) of the B shares are registered with VP Securities A/S (Euronext)

Following the stock split, the ticker symbol for ALK-Abelló’s B shares will remain “ALK B”. The company’s A and AA shares are unlisted and hence new ISIN codes etc. are not created for these actions.

ALK-Abello LIKE

For more information, please ccontact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjaer, mobile +45 3050 2014

About ALK
ALK is a global pharmaceutical company specializing in allergies and allergic asthma. It markets allergy immunotherapy treatments and other products and services for allergy sufferers and allergists. Based at Horsholm, Denmark, ALK employs approximately 2,600 people worldwide and is listed on Nasdaq Copenhagen. More information on www.alk.net.

Sallie R. Loera